Dyslipidemia treatment: current considerations and unmet needs
Related Experiment Videos
Shaista Malik1, Moti L Kashyap
1Department of Veterans Affairs Healthcare System, University of California, Long Beach 90822, USA. smalik@uci.edu
Abstract:
Monumental evidence from clinical trials indicates an approximately 30% reduction in atheroslcerotic cardiovascular disease (ASCVD) risk using monotherapy with lipid-regulating drugs in dyslipidemic patients. In order to achieve greater reductions in risk, other approaches are necessary, including improvements in technology designed to assess ASCVD risk. Recent preliminary, but encouraging evidence indicates that by combining drugs that have different mechanisms of action on lipid metabolism yields not only an additive effect on the lipoprotein spectrum, but also reduces ASCVD events. New studies indicate that niacin potently increases high-density lipoproteins (HDL) by inhibiting HDL catabolism and decreases hepatic production of atherogenic very-low- and low-density lipoproteins by inhibiting the key enzyme for triglyceride synthesis (diacylglycerol acyltransferase). Statins, fibrates, bile acid sequestrants and ezetimibe have mechanisms that are different. Combination therapy using statins and niacin not only safely corrects dyslipidemia, but also yields ASCVD risk reduction significantly in excess of the 30% seen with monotherapy. Newer drugs with different mechanisms of action or combinations of new formulations have recently become available. Drug discovery research is likely to yield additional agents. Clinical trials focused on combination therapies to reduce ASCVD risk well beyond 30% need to be conducted to establish the rationale for further reducing the incidence of the primary cause of death today.
Insights
Combining lipid-regulating drugs like statins and niacin offers greater atherosclerotic cardiovascular disease (ASCVD) risk reduction than monotherapy. Further research is needed to establish combination therapies for significant ASCVD event reduction.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Lipid Metabolism
Background:
- Monotherapy with lipid-regulating drugs reduces atherosclerotic cardiovascular disease (ASCVD) risk by approximately 30% in dyslipidemic patients.
- Greater ASCVD risk reduction necessitates novel therapeutic strategies beyond current monotherapies.
- Emerging evidence supports combination drug therapy for enhanced lipoprotein management and ASCVD event reduction.
Purpose of the Study:
- To evaluate the efficacy of combination therapy in achieving ASCVD risk reduction exceeding 30%.
- To explore the synergistic effects of drugs with different lipid-modulating mechanisms.
- To highlight the potential of novel drug formulations and combination therapies.
Main Methods:
- Review of clinical trial evidence on lipid-regulating drug monotherapy and combination therapy.
- Analysis of studies investigating the mechanisms of action for niacin, statins, and other lipid-lowering agents.
- Examination of preliminary data on combination therapy outcomes in dyslipidemic patients.
Main Results:
- Niacin increases high-density lipoproteins (HDL) by inhibiting catabolism and decreases very-low- and low-density lipoproteins (VLDL/LDL) by inhibiting triglyceride synthesis.
- Combination therapy with statins and niacin demonstrates safe and effective dyslipidemia correction.
- Combination therapy yields ASCVD risk reduction significantly greater than the 30% observed with monotherapy.
Conclusions:
- Combination therapy, particularly with statins and niacin, offers superior ASCVD risk reduction compared to monotherapy.
- Newer drugs and formulations with distinct mechanisms of action are becoming available.
- Further clinical trials are essential to validate combination therapies for substantially reducing ASCVD incidence.
Related Concept Videos
01:26Atherosclerosis III: Management
01:26Angina IV: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:24Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
01:18Lipids: Dietary Sources and Requirements
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...